Vijaya Diagnostic Centre Ltd approves FY26 dividend, ESOP grant, and MRI LLP acquisition
Vijaya Diagnostic Centre · Healthcare Services
Key highlights
- Recommended final dividend of ₹2/- per share for FY ended March 31, 2026, subject to AGM approval
- Granted 1,79,500 ESOPs at ₹784 per option under VDCL Employee Stock Option Plan 2018
- Approved acquisition of 100% MRI, EEG, NCV services business from MRI LLP for ~₹4.20 crore, completion in 3 months
Why it's rated notable: The results are declared but the filing states no profit or revenue figures, so the level stays at medium, while the ~₹4.20 Crore cash acquisition from a wholly owned subsidiary is low against the market value of ₹15,105 crore.
Original filing
Board Meeting Outcome for Outcome Of The Board Meeting Held On May 07, 2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- Jubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM QualityGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.